HANSOH PHARMA (03692): The application for the marketing permission of the O laipopeptide injection has been accepted by the National Medical Products Administration.

07:39 04/06/2026

Johnson Pharmaceuticals (03692) announced that on June 3, 2026, the group's innovative drug Olipotide peptide injection has obtained the market approval application (NDA) acceptance from the China National Medical Products Administration (NMPA), which is suitable for long-term weight management in obese or overweight adults. Olipotide is a weekly administered glucagon-like peptide-1 (GLP-1)/glucose-dependent insulinotropic peptide (GIP) dual receptor agonist independently developed by the group.

HANSOH PHARMA (03692) announced that on June 3, 2026, the Group's innovative drug Olaybopide Injection was accepted for market approval application (NDA) by the National Medical Products Administration (NMPA) of China. It is indicated for long-term weight management in obese or overweight adults. Olaybopide is a weekly GLP-1/GIP dual receptor agonist developed independently by the Group.

The entire market is chasing AI, while "big short" Burry is going against the trend and buying low: Adobe, Alibaba, and four other stocks are favored.

Buying low on Shenzhen Hepalink Pharmaceutical Group (09989) for two consecutive months, will the Hong Kong Stock Connect funds soon witness the reversal of the heparin cycle?

New Stock News | Leading supply chain company Andes Zhilian's Hong Kong IPO prospectus updated, achieving double high increase in revenue and net profit.

The entire market is chasing AI, while "big short" Burry is going against the trend and buying low: Adobe, Alibaba, and four other stocks are favored.

Buying low on Shenzhen Hepalink Pharmaceutical Group (09989) for two consecutive months, will the Hong Kong Stock Connect funds soon witness the reversal of the heparin cycle?

New Stock News | Leading supply chain company Andes Zhilian's Hong Kong IPO prospectus updated, achieving double high increase in revenue and net profit.